Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 5/20 | 0.35 |
| ▸ | CDK2 | P24941 | 5/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 11/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341877 | 0.94 | CCNE1 (0.36) | CCNE1CDK2CDK5GRM4RORC | |
| SCHEMBL1338714 | 0.93 | GRM4 (0.36) | CCNE1CDK2CDK5GRM4RORC | |
| SCHEMBL1342508 | 0.89 | CCNE1 (0.34) | CCNE1CDK2CDK5GRM4RORC | |
| SCHEMBL1342792 | 0.89 | GRM4 (0.34) | CCNE1CDK2CDK5GRM4RORC | |
| SCHEMBL1343468 | 0.88 | CCNE1 (0.37) | CCNE1CDK2CDK5GRM4RORC | |
| SCHEMBL1339934 | 0.88 | PTGDR2 (0.39) | GRM4RAB9A | |
| SCHEMBL1341812 | 0.88 | GRM4 (0.36) | GRM4RORCRAB9A | |
| SCHEMBL1342944 | 0.88 | GRM4 (0.38) | GRM4RORCRAB9A | |
| SCHEMBL1341960 | 0.87 | CLK1 (0.36) | CCNE1CDK2CDK5GRM4RORC | |
| SCHEMBL1341880 | 0.86 | RORC (0.35) | CCNE1CDK2CDK5GRM4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CCNE1 4257/4885CDK2 1019/4885CDK5 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.